Close Menu

Cellecta

The IP is based on the research of Emmanuelle Charpentier from the Hannover Medical School in Germany and Umea University in Sweden.

The company aims to commercialize the platform and related services by late 2018.

Using enhancements to RT-PCR, the firm is able to detect all protein-coding genes in a single-tube multiplex reaction, reducing costs for large-scale projects.

The genetic screening firm validated the modifications with a Phase I SBIR grant from NIH and is seeking a Phase II grant to target critical protein domains.

The company said the library will be made freely available to academic and non-profit investigators through the DECIPHER Project.

Exiqon, Cellecta

The company will use the NCI funding to discover and validate gene targets involved in breast cancer that may affect a panel of epithelial cells involved in breast cancer.

Pages

The US Centers for Disease Control and Prevention has identified a small group of breakthrough COVID-19 cases, the Wall Street Journal reports.

The New York Times reports that the US Department of Defense is to use genetic genealogy approaches to identify the remains of unknown soldiers.

Vox and Nature discuss the importance of preparing for the next pandemic.

In Nature this week: comparison of five circulating tumor DNA assays, resequencing analysis of lettuce gives insight into its domestication, and more.